Arrowhead Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is October - September.

Millions EUR. Fiscal year is Oct - Sep.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 20, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Market Capitalization	7,558	4,064	2,159	2,721	3,568	5,616
Market Cap Growth	210.58%	88.24%	-20.66%	-23.72%	-36.47%	49.72%
Enterprise Value	7,370	3,911	2,184	2,644	3,246	5,191
Last Close Price	53.84	28.97	17.46	25.31	33.60	52.20
PE Ratio	43.87	-	-	-	-	-
PS Ratio	8.13	5.75	678.12	11.96	14.38	47.07
PB Ratio	15.77	9.47	12.60	10.03	8.36	15.92
P/TBV Ratio	15.79	10.39	13.61	11.03	9.05	16.47
P/FCF Ratio	27.56	30.40	-	-	-	44.06
P/OCF Ratio	26.15	26.56	-	-	-	37.99
EV/Sales Ratio	7.96	5.53	686.02	11.63	13.09	43.51
EV/EBITDA Ratio	25.38	37.52	-	-	-	-
EV/EBIT Ratio	28.89	46.65	-	-	-	-
EV/FCF Ratio	26.87	29.25	-	-	-	40.72
Debt / Equity Ratio	1.24	1.48	4.46	1.34	0.20	0.06
Debt / EBITDA Ratio	2.04	5.36	-	-	-	-
Debt / FCF Ratio	2.17	4.74	-	-	-	0.17
Net Debt / Equity Ratio	-0.38	-0.34	0.91	-0.04	-0.69	-0.84
Net Debt / EBITDA Ratio	-0.66	-1.42	-0.30	0.06	1.71	2.43
Net Debt / FCF Ratio	-0.67	-1.11	-0.29	0.04	1.52	-2.32
Asset Turnover	0.83	0.66	0.00	0.33	0.35	0.22
Quick Ratio	3.26	4.73	6.57	3.75	2.67	2.58
Current Ratio	3.38	4.86	6.74	3.95	2.92	2.63
Return on Equity (ROE)	75.50%	8.67%	-254.98%	-59.33%	-42.68%	-32.36%
Return on Assets (ROA)	14.35%	4.87%	-39.43%	-17.58%	-15.91%	-15.11%
Return on Invested Capital (ROIC)	81.47%	16.53%	-187.71%	-101.05%	-180.86%	-127.38%
Return on Capital Employed (ROCE)	23.90%	8.30%	-58.00%	-31.10%	-32.30%	-26.40%
Earnings Yield	2.28%	-0.03%	-24.90%	-7.13%	-5.03%	-2.16%
FCF Yield	3.63%	3.29%	-25.10%	-11.48%	-5.40%	2.27%
Buyback Yield / Dilution	-10.94%	-11.67%	-12.21%	-1.26%	-1.62%	-3.00%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.